News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Final analysis of the PRECIOUS phase 3 trial
metastatic breast cancer/docwirenews.com
Jan 30, 2025, 08:44

Final analysis of the PRECIOUS phase 3 trial

Paolo Tarantino, Clinical Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared an article by Yutaka Yamamoto, et al. on X:

“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology.

Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Authors: Yutaka Yamamoto, et al.

Final analysis of the PRECIOUS phase 3 trial

cancer Dana-Farber Cancer Institute fight against cancer Global fight against cancer Harvard Medical School Journal of Clinical Oncology metastatic breast cancer OncoDaily Oncology Paolo Tarantino pertuzumab Yutaka Yamamoto
Special Coverage
Science
Jan 30, 2025, 08:44
Final analysis of the PRECIOUS phase 3 trial
Blog
Jan 30, 2025, 08:41
On World Cancer Day, let’s honour those we’ve lost - Childhood Cancer International
Blog
Jan 30, 2025, 08:37
The newly elected ESO College Council held its first meeting in Milan - European School of Oncology
Blog
Jan 30, 2025, 08:35
Audra Moran: Ovarian Cancer Research Alliance joins with Rivkin Center for Ovarian Cancer Research in the mission to end ovarian cancer
Science
Jan 30, 2025, 08:33
Wafik S. El-Deiry: Heterogeneity in Cancer
Science
Jan 30, 2025, 08:31
Hung Trinh: Although immunotherapy has made breakthrough progress, its efficacy in solid tumours remains unsatisfactory
Dialogues
Jan 30, 2025, 06:40
ASCO24 Updates: Matthew Paul Smeltzer on Addressing Lung Cancer Screening Disparities
Blog
Jan 30, 2025, 06:24
Theresa Ermer: Surgical outcomes and complications after neoadjuvant chemoimmunotherapy for resectable NSCLC
Blog
Jan 30, 2025, 06:21
Luis Felipe Tapias: The potential impact of intraoperative assessment of margins in sublobar resections for lung cancer
Insight
Jan 30, 2025, 06:19
Senthil Kumar: First-Line Therapy for Advanced/Metastatic Penile Cancer
Insight
Jan 30, 2025, 06:15
NSCLC treated with EGFR inhibitors - EGFR Resisters
Science
Jan 30, 2025, 06:11
Long-term renal function after SABR for primary RCC, including solitary kidney patients by Vivian Tan et al.